It becomes necessary for pharmaceutical enterprises to make long-term strategic plans to deal with changes brought by policies after China’s proposal of the Made in China 2025 strategy. The intelligent manufacturing is not merely a great change to pharmaceutical enterprises, but also a process to analyze and look at the issues and intractable problems encountered in enterprises’ development.
What are the difficulties for pharmaceutical enterprises to achieve automation and informatization? How should Chinese pharmaceutical industry walk out own road of Industry 4.0?
Let’s listen to the ideas shared by pharmaceutical enterprises that have breakthroughs in intelligent manufacturing. The enterprise sharing this time is Shandong Shinva Medical Instrument Co., Ltd.
Company profile
As the first medical device manufacturer established by the Communist Party of China and Chinese People's Liberation Army in 1943, Shandong Shinva Medical Instrument Co., Ltd. successfully went public at Shanghai Stock Exchange (600587) in September 2002. With dozens of new products launched to the market every year, Shinva has possessed up to 14 China State-level New Products, and is the first enterprise that owns a "State-level Enterprise Technical Center" in the Chinese medical device industry.
Q&A
1. What corresponding strategic plans have you made in recent years since China’s proposal of the Made in China 2025 strategy?
Shinva has vigorously developed the automated and information-based pharmaceutical machinery and Equipment used in API manufacturing in recent years.
I. Form the R&D and production system of automated equipment classified by production of infusions, solid preparations, TCM preparations and blood products, and provide pharmaceutical enterprises with comprehensive and full services on equipment level from the two main directions of product type and product precision, to improve product precision and operation stability.
II. Recognize the current situation of automation construction of pharmaceutical enterprises, and make the part missed in previous enterprise automation the direction for new products and vigorous promotion.
III. Conduct layout of consulting services for new informatization products and intelligent plant construction, and establish a new independent plant to provide information products and services, with products including the ERP, WMS, MES and LIMS, etc. required by pharmaceutical enterprises.
IV. Integrate resources of each sector, fuse own automated equipment and information-based products, carry out practice in pharmaceutical enterprises, and construct the road of intelligent manufacturing together with them.
V. Business promotion: Provide consulting services for process R&D and process improvement, etc., and provide pharmaceutical enterprises with product test and R&D platform and relevant resources.
2. What intractable problems of the pharmaceutical industry do you think the intelligent plants could solve?
From bottom to top of architecture of intelligent manufacturing enterprises, the problems include:
Automation coverage of production equipment, operation stability of equipment, disunity of equipment data communication protocols, islands of equipment and system data, off-line quality control, interference of human factors in production, separation of intelligent system and automated equipment, absence of application of the new-generation IT, discrete procurement, plan, production, operation, sales and market information inside enterprise, failure to further optimize production and increase overall enterprise operation efficiency by using big data analysis.
All the above shall be overcome by pharmaceutical enterprises during constructing intelligent plants.
3. What is the biggest difficulty for the automatic and information-based transformation of plants? What are the solutions?
The automatic and information-based transformation of old plants will encounter some problems, and the big difficulties inclu...
(All Rights Reserved)